ALDH2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL320035	1.00	20/20
SCHEMBL320049	1.00	20/20
SCHEMBL320544	1.00	20/20
SCHEMBL555786	0.58	18/20
SCHEMBL554685	0.67	17/20
SCHEMBL571102	0.63	15/20
SCHEMBL311566	0.52	13/20
Isoformonentin (SCHEMBL73338)	0.75	12/20
SCHEMBL312883	0.64	11/20
SCHEMBL571388	0.71	10/20
SCHEMBL470779	0.53	10/20
SCHEMBL312809	0.52	10/20
SCHEMBL312253	0.60	9/20
Disulfiram (SCHEMBL27213)	1.00	7/20
SCHEMBL442690	0.73	7/20
SCHEMBL106453	0.48	7/20
SCHEMBL94548	0.48	7/20
SCHEMBL24804	1.00	6/20
SCHEMBL283865	0.86	6/20
Thiram (SCHEMBL381153)	0.83	6/20

Clinical trials — most relevant to ALDH2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Acetylcarnitine and Insulin Sensitivity	PHASE2	COMPLETED
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC	PHASE1/PHASE2	UNKNOWN
Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients	PHASE2	UNKNOWN
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension	PHASE2	NOT_YET_RECRUITING
The KHENERGY Study	PHASE2	COMPLETED
Clinical Effects of Alpha-Lipoic Acid in Advanced NSCLC	PHASE2	NOT_YET_RECRUITING
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease	PHASE2	COMPLETED
NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline	PHASE2	RECRUITING
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis	PHASE2	UNKNOWN
Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI)	PHASE2	RECRUITING
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients	PHASE2	COMPLETED
ALDH2 Single Nucleotide Polymorphisms and Prognosis of Esophageal Cancer Patients	nan	RECRUITING
Functional Investigation of Endothelial Function and Regenerative Cell Exhaustion	nan	NOT_YET_RECRUITING
Study of Protein Translocation in Patients With Beta-Oxidation Disorders	nan	COMPLETED
A Study Into the Underlying Biochemical Pathways Involved in Parkinson's Disease, Such as Mitochondrial (Cellular Powerhouse) Dysfunction	nan	COMPLETED
Environmental and Biological Monitoring Pilot Study for Polycyclic Aromatic Hydrocarbons in Linxian, China	nan	COMPLETED
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN)	nan	UNKNOWN
Tissue Sample Study for Mitochondrial Disorders	nan	ENROLLING_BY_INVITATION
Predicts Mortality by AST/ALT Ration in Patients with Sepsis and Septic Shock During ICU Admissin	nan	NOT_YET_RECRUITING
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population	nan	UNKNOWN
Effects of Parenteral L-carnitine Supplementation in Premature Neonates	nan	COMPLETED
A RETROspective Study of Patients With TK2d	nan	COMPLETED
ADH1B and ALDH Gene Variants and Lung Cancer Risk	nan	NOT_YET_RECRUITING
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine	nan	COMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development	nan	RECRUITING
Potential Synergistic Effect of Combined Blood Flow Restriction Training and Betaine Supplementation on Skeletal Muscle	nan	COMPLETED
Longitudinal Study of Mitochondrial Hepatopathies	nan	SUSPENDED
Nutraceutical Composition Containing Natural Products Derivatives on the Modulation of the Endocrine Neuroimmune Axis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ALDH2 binder may also engage these)

Protein	Name	Similarity
Q2XQV4	—	1.000	Q2XQV4 →
Q5RF00	—	1.000	Q5RF00 →
Q5R6B5	—	1.000	Q5R6B5 →
P12762	—	1.000	P12762 →
P11884	—	1.000	P11884 →
P81178	—	0.999	P81178 →
P47738	—	0.999	P47738 →
Q8MI17	—	0.997	Q8MI17 →
C7A2A0	—	0.997	C7A2A0 →
Q66HF8	—	0.997	Q66HF8 →
ALDH1B1	Aldehyde dehydrogenase X, mitochondrial	0.997	landscape →
Q19A30	—	0.996	Q19A30 →
Q25417	—	0.995	Q25417 →
P51977	—	0.995	P51977 →
Q9SU63	—	0.995	Q9SU63 →
P48644	—	0.994	P48644 →
Q9CZS1	—	0.994	Q9CZS1 →
Q8HYE4	—	0.994	Q8HYE4 →
O93344	—	0.994	O93344 →
ALDH1A3	Retinaldehyde dehydrogenase 3	0.994	landscape →
ALDH1A1	Aldehyde dehydrogenase 1A1	0.994	landscape →
P56533	—	0.994	P56533 →
P20000	—	0.993	P20000 →
B7L441	—	0.993	B7L441 →
Q83R90	—	0.992	Q83R90 →
P13601	—	0.992	P13601 →
C6KEM4	—	0.992	C6KEM4 →
Q9JHW9	—	0.992	Q9JHW9 →
B5Z1R1	—	0.992	B5Z1R1 →
P15437	—	0.992	P15437 →